5月21日 - ** 受增资消息影响，NervGen Pharma（NGEN.O）盘后股价下跌22.8%，报2.84美元
** 这家加拿大生物制药公司已启动 (link) 股票、认股权证及预付认股权证的发行，但未披露交易规模
** 计划将募集净额用于推进其脊髓损伤药物 NVG-291 的临床研究，并用于一般企业运营及营运资金
** Leerink与TD Cowen担任联合簿记管理人
** NGEN股价周四收跌1.6%至3.68美元，年内累计跌幅达34%
** 据伦敦证券交易所集团（LSEG）数据显示，基于约8220万股流通股，该公司市值约为3亿美元
** 7位分析师均给予该股“买入”评级；目标价中位数为8.20美元
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.